Biosimilars are the generic version of
biological. A biosimilar is a biologic therapeutic item which is duplicate of a
unique item that is produced by an alternate organization. It is the new buzz
word in pharmaceutical industry. Biosimilars are highly comparable to licensed
reference product not accept minor differences in clinically passive
components; also there are no clinically needful disparities between the
biologicals and the reference product in terms of safety, purity, and potency.

Biologic Drugs are genetically occurred from
a living organism, such as a virus, protein, to maintain the body’s natural
response to infections and diseases. Biologics target proteins, and cells responsible
for the manifestation and damage of rheumatoid arthritis and other types of
inflammatory arthritis. The proteins targeted include tumours necrosis factor
(TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6), which shows effect in
joint inflammation. Biologics are reserved for people whose arthritis has not retorted
well to disease-modifying anti rheumatic drugs (DMARDs).